Stock Taper
SYBX
SYNLOGIC, INC.
OTC
$1.17
▼ DOWN 4.10% (-0.05)

KEY STATISTICS

Market Cap$13.69 M
52w High$1.87
52w Low$0.54
Dividend Yield
Frequency
P/E-19.50
Volume478
Shares Out.11.70M

COMPANY

LEADERSHIP

Mary Beth Dooley
CHIEF EXECUTIVE
Mary Beth Dooley

COMPENSATION 2026

Salary$387,625
Stock Awards$0
Incentive Plan Pay$128,885
All Other Comp.$10,600
Total$1,708,313

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 30, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2023-09-28Reverse1:15
2017-08-28Reverse1:7

PRICE

$1.17 ▼ DOWN 4.10% (−$0.05)
OVERLAYS
$1.17$1.18$1.20$1.2111:28 AM12:13 PM12:58 PM1:42 PM2:27 PM3:12 PM3:57 PM1.17

About Synlogic, Inc.

https://www.synlogictx.com ↗

Synlogic, Inc. is a Cambridge-based clinical-stage biopharmaceutical company developing synthetic biotic medicines for metabolic, immunological, and cancer indications, with multiple drug candidates in Phase I and II trials.

INDUSTRY

Biotechnology

A SERVICE SYNLOGIC, INC. IS KNOWN FOR

Synthetic Biotic Drug Development Platform

Synlogic, a clinical-stage biotech developing oral Synthetic Biotics, halted its Phase 3 PKU trial, laid off 90% of staff, and is exploring strategic options, casting uncertainty on its future pipeline.

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

DIRECTOR, 10 PERCENT OWNER:
New Enterprise Associates 14, L.P.
Purchase · 2.6M shares
2026-07-27
OFFICER: SEE REMARKS BELOW
Dooley Mary Beth
Sale · 157 shares
2025-10-29

SECTORS PEERS

PEERPRICE
CING$5.10COMPARE
BCTX$3.57COMPARE
LEXX$14.15COMPARE
ALLR$1.42COMPARE
CUPR$3.16COMPARE
PCSA$2.06COMPARE
CRIS$1.35COMPARE